Can a One-Two drug punch beat back Hard-to-Treat myeloma?
NCT ID NCT07720843
First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time
Summary
This early-phase trial is testing whether combining two targeted drugs—talquetamab and belantamab mafodotin—can safely control multiple myeloma that has returned or stopped responding to prior treatments. The study enrolls adults with myeloma who have already tried at least one prior therapy, including common drug classes. After an initial treatment period, participants may switch to a maintenance regimen with belantamab and pomalidomide. The goal is to find the best doses and assess the combination's safety and potential effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a combination of two targeted drugs: talquetamab and belantamab mafodotin, followed by maintenance with belantamab mafodotin and pomalidomide
- What this could lead to
- If successful, this approach could offer a new treatment option for people with multiple myeloma that has stopped responding to standard therapies.
- What could go wrong
- This is an early-phase trial with a small number of participants, so the safety and effectiveness of the combination are not yet known. Side effects, including eye problems from belantamab, are a concern.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- CAR-T breakthroughs come with infection risks – new study aims to decode them
- Double-barreled CAR t therapy takes aim at hard-to-treat myeloma
- Can a drug stop dangerous side effects of new myeloma therapies?
- New study examines belantamab combos for myeloma relapse
- New hope for myeloma: adaptive trial tests smarter drug combos
- Brain training before CAR-T may protect memory, study hopes